- At issue is whether Sanofi's (SNY +0.2%) and Regeneron's (REGN -1.3%) Dupixent - currently awaiting U.S. approval (expected next week) - infringes on an Amgen (AMGN -1.3%) patent for a failed asthma treatment.
- The lawsuit filed by the duo today preempts what is expected to be one brought by Amgen (which recently received a favorable ruling in its lawsuit against the two over Praluent).
- Annual sales for Dupixent are predicted to top $5B by 2023.